HB1801
Phase 3Small molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.HB1801 is one of 90 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
4
Indications
10
Total Trials
9
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
702 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1HB1801
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2027
Phase 2Not yet recruiting
Breast Cancer
NCT07116824
Phase 1/2Not yet recruiting
Locally Advanced or Metastatic Solid Tumors
NCT06682611
Phase 2/3Not yet recruiting
Non-Small Cell Lung Cancer
NCT06319313
Phase 3Active, not recruiting
HER2-Positive Breast Cancer
NCT06747338
Phase 3Recruiting
Breast Cancer
NCT05838066
Clinical
Trials by Indication[1]
Breast Cancer5 trials
Non-Small Cell Lung Cancer2 trials
Locally Advanced or Metastatic Solid Tumors1 trial
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 1/2·NCT06682611·380 enrolled
HER2-negative Breast Cancer1 trial
HER2-positive Breast Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HB1801. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details